-
2
-
-
33749177293
-
The burden of musculoskelet al disease – a global perspective
-
Brooks PM. The burden of musculoskelet al disease – a global perspective. Clin Rheumatol. 2006;25(6):778–781
-
(2006)
Clin Rheumatol
, vol.25
, Issue.6
, pp. 778-781
-
-
Brooks, P.M.1
-
3
-
-
77957196913
-
Rheumatoid arthritis
-
Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108
-
(2010)
Lancet
, vol.376
, Issue.9746
, pp. 1094-1108
-
-
Scott, D.L.1
Wolfe, F.2
Huizinga, T.3
-
4
-
-
84855172814
-
The pathogenesis of rheumatoid arthritis
-
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219
-
(2011)
N Engl J Med
, vol.365
, Issue.23
, pp. 2205-2219
-
-
McInnes, I.B.1
Schett, G.2
-
5
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–975
-
(2010)
Ann Rheum Dis
, vol.69
, Issue.6
, pp. 964-975
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
-
6
-
-
84893772728
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
-
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.3
, pp. 492-509
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
-
7
-
-
77950307115
-
T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force
-
Smolen JS, Aletaha D, Bijlsma JW, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637
-
(2010)
Ann Rheum Dis
, vol.69
, Issue.4
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
-
8
-
-
3242677099
-
Effect of a treatment strategy of tight control for rheumatoid arthritis (The TICORA study): A single-blind randomised controlled trial
-
Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–269
-
(2004)
Lancet
, vol.364
, Issue.9430
, pp. 263-269
-
-
Grigor, C.1
Capell, H.2
Stirling, A.3
-
9
-
-
84899767403
-
Lower than expected levels of DMARD acquisition immediately pre and post biologic initiation in rheumatoid arthritis patients
-
Choquette D, Thomas O, Arundine M. Lower than expected levels of DMARD acquisition immediately pre and post biologic initiation in rheumatoid arthritis patients. Arthritis Rheum. 2012;64(Suppl 10):1841
-
(2012)
Arthritis Rheum
, vol.64
-
-
Choquette, D.1
Thomas, O.2
Arundine, M.3
-
10
-
-
84888348574
-
The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis
-
Ruderman EM. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis. Bull Hosp Jt Dis. 2013;2013(71 Suppl 1):S29–S32
-
(2013)
Bull Hosp Jt Dis
, vol.2013
, pp. 29-32
-
-
Ruderman, E.M.1
-
11
-
-
84891749397
-
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension
-
Keystone EC, Breedveld FC, van der Heijde D, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5–14
-
(2014)
J Rheumatol
, vol.41
, Issue.1
, pp. 5-14
-
-
Keystone, E.C.1
Breedveld, F.C.2
Van Der Heijde, D.3
-
12
-
-
84890900104
-
Etanercept for the treatment of rheumatoid arthritis
-
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525
-
(2013)
Cochrane Database Syst Rev
, vol.5
-
-
Lethaby, A.1
Lopez-Olivo, M.A.2
Maxwell, L.3
Burls, A.4
Tugwell, P.5
Wells, G.A.6
-
13
-
-
84922564119
-
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis
-
Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102
-
(2014)
Health Qual Life Outcomes
, vol.12
-
-
Jansen, J.P.1
Buckley, F.2
Dejonckheere, F.3
Ogale, S.4
-
14
-
-
84888332089
-
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis
-
Castrejón I, Gibson KA, Pincus T. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis. 2013;2013(71 Suppl 1):S20–S28
-
(2013)
Bull Hosp Jt Dis
, vol.2013
, pp. 20-28
-
-
Castrejón, I.1
Gibson, K.A.2
Pincus, T.3
-
15
-
-
84888358290
-
Update on methotrexate as the anchor drug for rheumatoid arthritis
-
Pincus T, Gibson KA, Castrejón I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis. 2013;2013(71 Suppl 1):S9–S19
-
(2013)
Bull Hosp Jt Dis
, vol.2013
, pp. 9-19
-
-
Pincus, T.1
Gibson, K.A.2
Castrejón, I.3
-
16
-
-
84936852067
-
Impact of biologics with and without concomitant MTX and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken)
-
Zhang J, Xie F, Delzell E, et al. Impact of biologics with and without concomitant MTX and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken). Epub 2014 Nov 4
-
(2014)
Epub
-
-
Zhang, J.1
Xie, F.2
Delzell, E.3
-
17
-
-
84887426711
-
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
-
Emery P, Sebba A, Huizinga TWJ. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897–1904
-
(2013)
Ann Rheum Dis
, vol.72
, Issue.12
, pp. 1897-1904
-
-
Emery, P.1
Sebba, A.2
Huizinga, T.3
-
18
-
-
46049108174
-
Utilization of biologic agents in rheumatoid arthritis in the United States: Analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy
-
Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis. 2008;66(2):77–85
-
(2008)
Bull NYU Hosp Jt Dis
, vol.66
, Issue.2
, pp. 77-85
-
-
Yazici, Y.1
Shi, N.2
John, A.3
-
19
-
-
79952359578
-
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
-
Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583–589
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.4
, pp. 583-589
-
-
Soliman, M.M.1
Ashcroft, D.M.2
Watson, K.D.3
Lunt, M.4
Symmons, D.5
Hyrich, K.L.6
-
21
-
-
84876701598
-
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: Results from a phase III, international, multicenter, parallel-arm, open-label study
-
Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013;65(5):718–728
-
(2013)
Arthritis Care Res (Hoboken)
, vol.65
, Issue.5
, pp. 718-728
-
-
Nash, P.1
Nayiager, S.2
Genovese, M.C.3
-
22
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37
-
(2006)
Arthritis Rheum
, vol.54
, Issue.1
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
-
23
-
-
0036400340
-
Anakinra as a new therapeutic option in rheumatoid arthritis: Clinical results and perspectives
-
Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol. 2002;20(5 Suppl 27):S32–S34
-
(2002)
Clin Exp Rheumatol
, vol.20
, pp. 32-34
-
-
Bresnihan, B.1
-
24
-
-
84900822066
-
Certolizumab pegol in rheumatoid arthritis: Current update
-
Fechtenbaum M, Md Yusof MY, Emery P. Certolizumab pegol in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2014;14(6): 841–850
-
(2014)
Expert Opin Biol Ther
, vol.14
, Issue.6
, pp. 841-850
-
-
Fechtenbaum, M.1
Md Yusof, M.Y.2
Emery, P.3
-
25
-
-
84855341008
-
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial
-
Curtis JR, Yang S, Chen L, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012;71(2):206–212
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.2
, pp. 206-212
-
-
Curtis, J.R.1
Yang, S.2
Chen, L.3
-
26
-
-
84892449972
-
Remission in rheumatoid arthritis patients treated with etanercept monotherapy: Clinical practice and clinical trial experience
-
Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience. Clin Exp Rheumatol. 2013;31(6):919–925
-
(2013)
Clin Exp Rheumatol
, vol.31
, Issue.6
, pp. 919-925
-
-
Cannon, G.W.1
Wang, B.C.2
Park, G.S.3
Koenig, A.4
Collier, D.H.5
Keystone, E.C.6
-
27
-
-
84879891418
-
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Results through 2 years of the GO-FORWARD study extension
-
Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013;40(7):1097–1103
-
(2013)
J Rheumatol
, vol.40
, Issue.7
, pp. 1097-1103
-
-
Keystone, E.C.1
Genovese, M.C.2
Hall, S.3
-
28
-
-
84861827682
-
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: Results from the GO-FORWARD study
-
Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol. 2012;39(6):1185–1191
-
(2012)
J Rheumatol
, vol.39
, Issue.6
, pp. 1185-1191
-
-
Genovese, M.C.1
Han, C.2
Keystone, E.C.3
-
29
-
-
84893721202
-
Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
-
Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516–528
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.3
, pp. 516-528
-
-
Nam, J.L.1
Ramiro, S.2
Gaujoux-Viala, C.3
-
30
-
-
85007158185
-
Sustainability of rituximab therapy in different treatment strategies: Results of a 3-year followup of a german biologics register
-
Richter A, Strangfeld A, Herzer P, et al. Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a german biologics register. Arthritis Care Res (Hoboken). 2014;66(11): 1627–1633
-
(2014)
Arthritis Care Res (Hoboken)
, vol.66
, Issue.11
, pp. 1627-1633
-
-
Richter, A.1
Strangfeld, A.2
Herzer, P.3
-
31
-
-
84899154465
-
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): Six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
-
Wendler J, Burmester GR, Sörensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014;16(2):R80
-
(2014)
Arthritis Res Ther
, vol.16
, Issue.2
-
-
Wendler, J.1
Burmester, G.R.2
Sörensen, H.3
-
32
-
-
84877275257
-
ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial
-
Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550
-
(2013)
Lancet
, vol.381
, Issue.9877
, pp. 1541-1550
-
-
Gabay, C.1
Emery, P.2
Van Vollenhoven, R.3
-
33
-
-
84904035777
-
Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
-
Nakashima Y, Kondo M, Miyahara H, Iwamoto Y. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab. Drug Des Devel Ther. 2014;8:913–919
-
(2014)
Drug Des Devel Ther
, vol.8
, pp. 913-919
-
-
Nakashima, Y.1
Kondo, M.2
Miyahara, H.3
Iwamoto, Y.4
-
34
-
-
84902593564
-
ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis
-
Lee EB, Fleischmann R, Hall S, et al; ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386
-
(2014)
N Engl J Med
, vol.370
, Issue.25
, pp. 2377-2386
-
-
Lee, E.B.1
Fleischmann, R.2
Hall, S.3
-
35
-
-
0036275436
-
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
-
Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6): 1470–1479
-
(2002)
Arthritis Rheum
, vol.46
, Issue.6
, pp. 1470-1479
-
-
Moreland, L.W.1
Alten, R.2
Van Den Bosch, F.3
-
36
-
-
70449709528
-
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial
-
Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11): 1708–1714
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.11
, pp. 1708-1714
-
-
Schiff, M.1
Pritchard, C.2
Huffstutter, J.E.3
-
38
-
-
84867401801
-
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: Data from the ‘Orencia and Rheumatoid Arthritis’ registry
-
Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–1819
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.11
, pp. 1815-1819
-
-
Gottenberg, J.E.1
Ravaud, P.2
Cantagrel, A.3
-
39
-
-
11144355274
-
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
-
van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516
-
(2004)
Ann Rheum Dis
, vol.63
, Issue.5
, pp. 508-516
-
-
Van De Putte, L.B.1
Atkins, C.2
Malaise, M.3
-
40
-
-
0036845130
-
Long-term safety and maintenance of clinical improvement following treatment with anakinra (Recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial
-
Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(11): 2838–2846
-
(2002)
Arthritis Rheum
, vol.46
, Issue.11
, pp. 2838-2846
-
-
Nuki, G.1
Bresnihan, B.2
Bear, M.B.3
McCabe, D.4
-
41
-
-
17444394445
-
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
-
Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–2204
-
(1998)
Arthritis Rheum
, vol.41
, Issue.12
, pp. 2196-2204
-
-
Bresnihan, B.1
Alvaro-Gracia, J.M.2
Cobby, M.3
-
42
-
-
2642550601
-
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial
-
Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol. 2004;31(6):1103–1111
-
(2004)
J Rheumatol
, vol.31
, Issue.6
, pp. 1103-1111
-
-
Bresnihan, B.1
Newmark, R.2
Robbins, S.3
Genant, H.K.4
-
43
-
-
67449123606
-
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study
-
Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6): 805–811
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.6
, pp. 805-811
-
-
Fleischmann, R.1
Vencovsky, J.2
Van Vollenhoven, R.F.3
-
44
-
-
84870317631
-
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study. Rheumatology (Oxford
-
Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford, England). 2012;51(12):2204–2214
-
(2012)
England)
, vol.51
, Issue.12
, pp. 2204-2214
-
-
Weinblatt, M.E.1
Fleischmann, R.2
Huizinga, T.W.3
-
45
-
-
0034735827
-
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
-
Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593
-
(2000)
N Engl J Med
, vol.343
, Issue.22
, pp. 1586-1593
-
-
Bathon, J.M.1
Martin, R.W.2
Fleischmann, R.M.3
-
46
-
-
48149100741
-
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial
-
Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636): 375–382
-
(2008)
Lancet
, vol.372
, Issue.9636
, pp. 375-382
-
-
Emery, P.1
Breedveld, F.C.2
Hall, S.3
-
47
-
-
77649159374
-
Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept- methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study
-
Emery P, Breedveld F, van der Heijde D, et al; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept- methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum. 2010;62(3):674–682
-
(2010)
Arthritis Rheum
, vol.62
, Issue.3
, pp. 674-682
-
-
Emery, P.1
Breedveld, F.2
Van Der Heijde, D.3
-
48
-
-
33750356014
-
Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study
-
van Riel PL, Taggart AJ, Sany J, et al; Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis. 2006;65(11):1478–1483
-
(2006)
Ann Rheum Dis
, vol.65
, Issue.11
, pp. 1478-1483
-
-
Van Riel, P.L.1
Taggart, A.J.2
Sany, J.3
-
49
-
-
79961102216
-
Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study
-
Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38(8): 1585–1592
-
(2011)
J Rheumatol
, vol.38
, Issue.8
, pp. 1585-1592
-
-
Kameda, H.1
Kanbe, K.2
Sato, E.3
-
50
-
-
84927637562
-
The Canadian methotrexate and etanercept outcome study: A randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
-
Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2014;73(12):2144–2151
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.12
, pp. 2144-2151
-
-
Pope, J.E.1
Haraoui, B.2
Thorne, J.C.3
Vieira, A.4
Poulin-Costello, M.5
Keystone, E.C.6
-
51
-
-
36749002002
-
Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
-
Kristensen LE, Saxne T, Nilsson J, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8(6):R174
-
(2006)
Arthritis Res Ther
, vol.8
, Issue.6
-
-
Kristensen, L.E.1
Saxne, T.2
Nilsson, J.3
-
52
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–1563
-
(1998)
Arthritis Rheum
, vol.41
, Issue.9
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
-
53
-
-
33745037669
-
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
-
Hyrich KL, Symmons DPM, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(6):1786–1794
-
(2006)
Arthritis Rheum
, vol.54
, Issue.6
, pp. 1786-1794
-
-
Hyrich, K.L.1
Symmons, D.2
Watson, K.D.3
Silman, A.J.4
-
54
-
-
2942537697
-
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
-
Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581
-
(2004)
N Engl J Med
, vol.350
, Issue.25
, pp. 2572-2581
-
-
Edwards, J.1
Szczepanski, L.2
Szechinski, J.3
-
55
-
-
54349107275
-
Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate
-
Owczarczyk K, Hellmann M, Fliedner G, et al. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis. 2008;67(11):1648–1649
-
(2008)
Ann Rheum Dis
, vol.67
, Issue.11
, pp. 1648-1649
-
-
Owczarczyk, K.1
Hellmann, M.2
Fliedner, G.3
-
56
-
-
2642558925
-
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial
-
Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761–1769
-
(2004)
Arthritis Rheum
, vol.50
, Issue.6
, pp. 1761-1769
-
-
Nishimoto, N.1
Yoshizaki, K.2
Miyasaka, N.3
-
57
-
-
34447300492
-
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
-
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167
-
(2007)
Ann Rheum Dis
, vol.66
, Issue.9
, pp. 1162-1167
-
-
Nishimoto, N.1
Hashimoto, J.2
Miyasaka, N.3
-
58
-
-
73449118587
-
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
-
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69(1):88–96
-
(2010)
Ann Rheum Dis
, vol.69
, Issue.1
, pp. 88-96
-
-
Jones, G.1
Sebba, A.2
Gu, J.3
-
59
-
-
84897971056
-
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: The ACT-RAY study
-
Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–809
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.5
, pp. 803-809
-
-
Dougados, M.1
Kissel, K.2
Conaghan, P.G.3
-
60
-
-
84906100884
-
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
-
Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop. 2014;5(4):504–511
-
(2014)
World J Orthop
, vol.5
, Issue.4
, pp. 504-511
-
-
Lundquist, L.M.1
Cole, S.W.2
Sikes, M.L.3
-
61
-
-
84864716411
-
ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
-
Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507
-
(2012)
N Engl J Med
, vol.367
, Issue.6
, pp. 495-507
-
-
Fleischmann, R.1
Kremer, J.2
Cush, J.3
-
62
-
-
84855833408
-
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis
-
Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275
-
(2012)
Plos One
, vol.7
, Issue.1
-
-
Aaltonen, K.J.1
Virkki, L.M.2
Malmivaara, A.3
Konttinen, Y.T.4
Nordström, D.C.5
Blom, M.6
-
63
-
-
84893803131
-
Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
-
Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529–535
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.3
, pp. 529-535
-
-
Ramiro, S.1
Gaujoux-Viala, C.2
Nam, J.L.3
-
64
-
-
10744223002
-
TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–681
-
(2004)
Lancet
, vol.363
, Issue.9410
, pp. 675-681
-
-
Klareskog, L.1
Van Der Heijde, D.2
De Jager, J.P.3
-
65
-
-
33646365588
-
TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
-
van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al; TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–1074
-
(2006)
Arthritis Rheum
, vol.54
, Issue.4
, pp. 1063-1074
-
-
Van Der Heijde, D.1
Klareskog, L.2
Rodriguez-Valverde, V.3
-
66
-
-
68049099274
-
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
-
Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8): 2272–2283
-
(2009)
Arthritis Rheum
, vol.60
, Issue.8
, pp. 2272-2283
-
-
Emery, P.1
Fleischmann, R.M.2
Moreland, L.W.3
-
67
-
-
84864703156
-
ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
-
van Vollenhoven RF, Fleischmann R, Cohen S, et al; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519
-
(2012)
N Engl J Med
, vol.367
, Issue.6
, pp. 508-519
-
-
Van Vollenhoven, R.F.1
Fleischmann, R.2
Cohen, S.3
-
68
-
-
84873707288
-
ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial
-
Burmester GR, Blanco R, Charles-Schoeman C, et al; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460
-
(2013)
Lancet
, vol.381
, Issue.9865
, pp. 451-460
-
-
Burmester, G.R.1
Blanco, R.2
Charles-Schoeman, C.3
-
69
-
-
84874656491
-
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
-
van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–172
-
(2013)
Nat Rev Rheumatol
, vol.9
, Issue.3
, pp. 164-172
-
-
Van Schouwenburg, P.A.1
Rispens, T.2
Wolbink, G.J.3
-
70
-
-
84867399904
-
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
-
Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914–1915
-
(2012)
Ann Rheum Dis
, vol.71
, Issue.11
, pp. 1914-1915
-
-
Krieckaert, C.L.1
Nurmohamed, M.T.2
Wolbink, G.J.3
-
71
-
-
84877809247
-
Immunogenicity and autoimmunity during anti-TNF therapy
-
Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12(7):703–708
-
(2013)
Autoimmun Rev
, vol.12
, Issue.7
, pp. 703-708
-
-
Atzeni, F.1
Talotta, R.2
Salaffi, F.3
-
72
-
-
33845660797
-
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
-
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12): 3782–3789
-
(2006)
Arthritis Rheum
, vol.54
, Issue.12
, pp. 3782-3789
-
-
Bendtzen, K.1
Geborek, P.2
Svenson, M.3
Larsson, L.4
Kapetanovic, M.C.5
Saxne, T.6
-
73
-
-
48549102501
-
Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement
-
Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20(4):431–435
-
(2008)
Curr Opin Immunol
, vol.20
, Issue.4
, pp. 431-435
-
-
Aarden, L.1
Ruuls, S.R.2
Wolbink, G.3
-
74
-
-
79751520384
-
Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis
-
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–89
-
(2010)
Clin Med Insights Arthritis Musculoskelet Disord
, vol.3
, pp. 81-89
-
-
Jones, G.1
Ding, C.2
-
75
-
-
34548667692
-
Predictors of infusion reactions during infliximab treatment in patients with arthritis
-
Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8(4):R131.
-
(2006)
Arthritis Res Ther
, vol.8
, Issue.4
-
-
Kapetanovic, M.C.1
Larsson, L.2
Truedsson, L.3
Sturfelt, G.4
Saxne, T.5
Geborek, P.6
|